Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ANDRX (ADRX) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (88)	5/23/1998 11:26:00 AM
From: Arthur Radley	Read Replies (1) \| Respond to of 127

Early! I thought the same thing but there are some milestones coming up fairly soon: 1) Waxman-Hatch period expires on July 3, 1998. This applies to the 30 month waiting period over HMR's Cardizem CD and ADRX's generic version. 2) Watson could increase its position in ADRX to 20% to benefit directly from the company becoming profitable. 2) ADRX is estimated to earn a profit as early as the 3Q. With the overall market ready to correct IMO, I would be hesitate to put any new money into the market.